Back to top
more

Blueprint Medicines (BPMC)

(Real Time Quote from BATS)

$85.56 USD

85.56
60,658

-0.44 (-0.51%)

Updated Oct 18, 2024 11:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe

by Zacks Equity Research

Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.

Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.09% and -4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Blueprint Medicines (BPMC) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

by Zacks Equity Research

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

by Zacks Equity Research

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

Blueprint Medicines (BPMC) Up 2.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM

by Zacks Equity Research

The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.

Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study

by Zacks Equity Research

AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.

Cocrystal Pharma (COCP) Jumps: Stock Rises 7.3%

by Zacks Equity Research

Cocrystal Pharma (COCP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Blueprint Medicines (BPMC) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

by Zacks Equity Research

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

by Ekta Bagri

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio in 2021

by Ekta Bagri

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug

by Zacks Equity Research

Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.

Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

by Zacks Equity Research

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

Amarin (AMRN) Surges: Stock Moves 9% Higher

by Zacks Equity Research

Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

    Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.